No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
NVS240621C92500
- 8.58
- 0.000.00%
15min DelayClose May 31 15:59 ET
0.00High0.00Low
8.58Open8.58Pre Close0 Volume92 Open Interest92.50Strike Price0.00Turnover38.56%IV0.65%PremiumJun 21, 2024Expiry Date10.63Intrinsic Value100Multiplier18DDays to Expiry0.00Time Value100Contract SizeAmericanOptions Type0.9053Delta0.0186Gamma9.13Leverage Ratio-0.0519Theta0.0427Rho8.26Eff Leverage0.0397Vega
Intraday
- 5D
- 1D
News
Express News | NYSE Order Imbalance 68931.0 Shares on Sell Side
Novartis (NVS) Reports Positive Long-Term Data on CSU Drug
Novartis Boasts Scemblix Beats Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia
Novartis Reports Positive Phase 3 Data for Remibrutinib for Chronic Hives
Novartis' Oral Drug For Chronic Skin Disease Candidate Shows Efficacy, Long-term Safety
On Friday, Novartis AG (NYSE:NVS) released new data that confirm the long-term efficacy and safety of remibrutinib, a highly selective Bruton's tyrosine kinase (BTK) inhibitor, in chronic spontaneous
Novartis Scemblix Phase III Data Shows Superior Efficacy With A Favorable Safety And Tolerability Profile Vs. Standard-Of-Care TKIs In Adults With Newly Diagnosed CML
Phase III ASC4FIRST trial met both primary endpoints with clinically meaningful and statistically significant results; Scemblix (asciminib) demonstrated superior MMR rates at week 48 vs. investigator-
Comments
$Esperion Therapeutics(ESPR.US$ Multiple sources indicate that Esperion's advancements and commercial success with its cholesterol-lowering drugs, NEXLIZET and NEXLETOL, have positioned it as defininte acquistion target for larger pharmaceutical companies. Esperion's drugs NEXLIZET and NEXLETOL now have primary prevention labels, NEXLIZET will soon become the drug of choice over a PCSK9 inhibitor says Texas based HeartPlace leading Cardio...
12
Stories you might have missed ![]()
Singapore’s private home sales down nearly half in February; 149 condos sold amid holiday lull
DEVELOPERS in Singapore sold 149 private homes in February, 47 per cent fewer than the 281 units moved in January, data released on Friday (Mar 15) by the Urban Redevelopment Authority showed.
Novartis invests US$256 million to expand Singapore plant
SWISS biopharma giant Novartis has invested US$256 million to expand its biopharm...
Singapore’s private home sales down nearly half in February; 149 condos sold amid holiday lull
DEVELOPERS in Singapore sold 149 private homes in February, 47 per cent fewer than the 281 units moved in January, data released on Friday (Mar 15) by the Urban Redevelopment Authority showed.
Novartis invests US$256 million to expand Singapore plant
SWISS biopharma giant Novartis has invested US$256 million to expand its biopharm...
7
Google's disappointing ad sales growth and AMD's lower revenue guidance have hurt investor sentiment, causing their shares to drop. Byron Allen's offer to acquire Paramount Global is seen as beneficial for shareholders, boosting its share price. Novartis AG's lower Q4 earnings and adjusted mid-term guidance have led to a share price decline.
JPMorgan analysts predict a strong uptake for Novartis's various treatments to boost the company's top line, with cost savings from restructuring aiding the bottom line. Morgan Stanley analysts note Novartis's need for external innovation to meet long-term growth ambitions.
Recent M&A activities💰 in January:
$Ambrx Biopharma(AMAM.US$ acquisition by $Johnson & Johnson(JNJ.US$
Aiolos Bio acquisition by $GlaxoSmithKline(GSK.US$
$Harpoon Therapeutics(HARP.US$ acquisition by $Merck & Co(MRK.US$
Calypso Biotech acquisition by $Novartis AG(NVS.US$
What companies will be next? 🤔
$Ambrx Biopharma(AMAM.US$ acquisition by $Johnson & Johnson(JNJ.US$
Aiolos Bio acquisition by $GlaxoSmithKline(GSK.US$
$Harpoon Therapeutics(HARP.US$ acquisition by $Merck & Co(MRK.US$
Calypso Biotech acquisition by $Novartis AG(NVS.US$
What companies will be next? 🤔
1
Read more